Xeris Biopharma Holdings Inc (XERS) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Xeris Biopharma Holdings Inc   (NASDAQ: XERS)


Xeris Biopharma Holdings Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Xeris Biopharma Holdings Inc's ROI in the first quarter of 2026?
Xeris Biopharma Holdings Inc achieved a return on average invested assets (ROI) of 4.97 % in its first quarter of 2026, this is above XERS's average return on investment of -25.07%.
Xeris Biopharma Holdings Inc invested over the 12 months ending in its first quarter of 2026 $260 million

Despite the deterioration in its net income, company has improved ROI compared to the fourth quarter of 2025.

Within the Healthcare sector 124 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2026 quarter, so far to 1037, from total ROI ranking in the fourth quarter of 2025 at 1853.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 26.15 % 18.83 % 3.9 % -7.43 % -12.58 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 273 274 254 240 220
Return On Investment (TTM) 4.97 % -4.04 % -9.32 % -8.97 % -7.69 %
XERS's Overall Ranking # 1037 # 1853 # 0 # 0 # 0
Seq. Investment Change TTM 5.37 % 9.37 % 6.8 % 2.5 % -0.74 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 13 -10 -21 -19 -16

XERS Company Profile >> Back to XERS Roi Comparisons >> See Annual XERS Return On Investment



Return On Investment XERS's Ranking
Within: No.
Industry # 48
Sector # 125
Overall # 1037

Return On Investment Statistics
High Average Low
15.54 %
-25.07 %
-170.59 %
(Mar 31 2021)   (Dec 31 2021)







Financial Statements
Xeris Biopharma Holdings Inc's I. Quarter Investments $ 273 Millions XERS's Balance sheet
Xeris Biopharma Holdings Inc's I. Quarter Income $ 4 Millions Quarterly XERS's Income Statement
XERS's Income by Division See XERS's Income by Division


XERS Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 242 189 227 271 214
Y / Y Investment Growth 28.02 % -16.73 % -16.05 % 26.36 % 63.72 %
Net Income in Millions 1 2 1 1 -245
Y / Y Net Income Growth -51.15 % 81.59 % -12.29 % - -
Annual Return On Investment 0.46 % 1.2 % 0.55 % 0.53 % -114.49 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 0.46 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
XERS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for XERS's Competitors
Subscribers only: Roi for Xeris Biopharma Holdings Inc's Suppliers
Subscribers only: Return On Investment for XERS's Customers

Other Ratios
XERS's Roa XERS's Inventory Turnover Ratio XERS's Growth Rates XERS's Dividend Statistics
XERS's Profitability Ratios XERS's Asset Turnover Ratio XERS's Dividend Growth
XERS's Roe XERS's Valuation Ratios XERS's Financial Strength Ratios XERS's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Agilent Technologies inc   13.44 %
Lifevantage Corp  13.20 %
Harmony Biosciences Holdings inc   13.07 %
Sbc Medical Group Holdings Incorporated  13.05 %
Progyny Inc   12.72 %
Insulet Corporation  12.55 %
Johnson and Johnson  12.51 %
Encompass Health Corporation  12.43 %
Globus Medical Inc   12.37 %
Regeneron Pharmaceuticals Inc   12.19 %
Medinotec Inc   12.13 %
Msa Safety Inc  12.11 %
Healthcare Services Group Inc   12.09 %
Amgen Inc   12.04 %
Alpha Pro Tech Ltd   11.97 %
Kiniksa Pharmaceuticals International Plc  11.92 %
Prestige Consumer Healthcare Inc   11.84 %
Mimedx Group Inc   11.75 %
Ufp Technologies Inc   11.69 %
Ligand Pharmaceuticals Incorporated  11.46 %
Solventum Corporation  11.19 %
Cryoport inc   11.16 %
Nature s Sunshine Products inc   11.05 %
Bristol myers Squibb Company  10.77 %
Tenet Healthcare Corp  10.65 %
Lemaitre Vascular Inc   10.61 %
Dr Reddy s Laboratories Limited  10.30 %
Siga Technologies Inc  10.04 %
Align Technology inc   9.99 %
Boston Scientific Corporation  9.95 %

Date modified: 2026-08-29T17:45:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.